Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | BLK | P51451 | 1/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566620 | 1.00 | CTSC (0.42) | CTSCEGFRALDH1A1MAP3K7HTR7 | |
| SCHEMBL24309808 | 0.91 | CTSC (0.46) | CTSCEGFRHTR7JAK2BLK | |
| SCHEMBL29566696 | 0.91 | CTSC (0.46) | CTSCEGFRHTR7JAK2BLK | |
| SCHEMBL29566415 | 0.89 | AURKA (0.37) | EGFRALDH1A1BRD4 | |
| SCHEMBL24310648 | 0.89 | AURKA (0.37) | EGFRALDH1A1BRD4 | |
| SCHEMBL24309771 | 0.87 | PTK2 (0.35) | EGFRHTR7BRD4JAK2 | |
| SCHEMBL29567013 | 0.87 | PTK2 (0.35) | EGFRHTR7BRD4JAK2 | |
| SCHEMBL29566756 | 0.86 | CTSC (0.39) | CTSCALDH1A1BRD4JAK2JAK3 | |
| SCHEMBL26808472 | 0.86 | CTSC (0.39) | CTSCALDH1A1BRD4JAK2JAK3 | |
| SCHEMBL29567018 | 0.84 | HTR6 (0.35) | CTSCHTR7BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CTSC 879/4885EGFR 818/4885ALDH1A1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.